Acute Ischemic Stroke Registry for Endovascular Treatment

Acute Ischemic Stroke Registry for Endovascular Treatment in China

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05213754

Enrollment

500

Registered

2022-01-28

Start date

2021-01-01

Completion date

2023-06-30

Last updated

2022-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Keywords

Acute ischemic stroke, Endovascular treatment, Outcome, Registry

Brief summary

The Acute Ischemic Stroke Registry for Endovascular Treatment (AIS-EVT) is an academic, prospective, multicenter, observational registry study. Consecutive stroke patients treated with endovascular treatment will be enrolled in stroke centers. Baseline information and clinical follow-up information at 90 days of stroke onset are collected. Data collected include demographics, comorbidities, pathogenesis, blood pressures, stroke severity on admission, time intervals, reperfusion condition, and functional outcome, et al.

Interventions

PROCEDUREEndovascular Treatment

Re-open the occluded cerebral artery using endovascular treatment

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Diagnosis of acute ischemic stroke; 2. Imaging confirmed intracranial large vessel occlusion: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1/M2), anterior cerebral artery (ACA A1/A2), basilar artery (BA), vertebral artery (VA V4), and posterior cerebral artery (PCA P1); 3. Initiation of any type of endovascular treatment, including intra-arterial thrombolysis, mechanical thrombectomy, aspiration, angioplasty, and stenting; 4. Verbal and written informed consent was provided at the time of admission by patients or their legal authorized representatives.

Exclusion criteria

No evidence of large vessel occlusion on digital subtraction angiography.

Design outcomes

Primary

Measure	Time frame	Description
The modified Rankin Scale score at 90 days	90 days	The range of the modified Rankin Scale is from 0 to 6. A higher score indicates a worse outcome. 0-No symptoms; 1-No significant disability; 2-Slight disability; 3-Moderate disability; 4-Moderately severe disability; 5-Severe disability; 6-Dead.

Countries

China

Contacts

Primary ContactXunming Ji, MD

jixm@ccmu.edu.cn010-83198952

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026